Replies to post #107668 on Biotech Values

[DewDiligence]

Even now, I don't think you understand how the recouped development costs worked (even though I've explained it multiple times). If you understood how it worked, you would realize that your posts on this subject are nonsensical.

I've never mentioned what NVS would recoup. I've only been concerned with what Momenta's liability was.

The two numbers are directly proportional so if you know one you know the other.

[zipjet]

It's funny that you aren't trying to back up your 20% Cogs prediction.

20% for COGS is ballpark. We don't know exactly because of mixing COGS and the fixed percentage SGNA.

It appears to me that using an operating margin of 61% works for 3Q and my guess is that moves toward 66% over time as COGS drop further. At least that is the way I will model it.

Actual sales and these margins certainly put your estimates in the correct perspective.

ij